Jiangsu Kanion Pharmaceutical Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
1
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 14, 2027The maintenance fee for Salts formed by 2-(1-acyloxy-n-pentyl) benzoic acid and basic amino acid or aminoguanidine, and preparation method and application thereof (US 11,814,352) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 2 fees due Oct 16 to 28, 2027 · next Oct 16
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,067,040 | Cinnamomi and poria composition and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,988,361 | Anti-enterovirus 71 thiadiazolidine derivative In force · USPTO record | In force | USPTO record | |
| US 10,227,339 | Salt Form and Crystal Form of 1,2,5-Thiadiazolidin-1,1-Dioxide, Preparation Method Thereof and Intermediate In force · High confidence | In force | High confidence | |
| US 10,633,351 | Halogenated Compound and Axially Chiral Isomer Thereof In force · High confidence | In force | High confidence | |
| US 11,220,525 | Method for dynamically removing recombinant human nerve growth factor precursor by hydrophobic interaction chromatography In force · USPTO record | In force | USPTO record | |
| US 11,524,041 | Ginkgo diterpene lactone composition In force · USPTO record | In force | USPTO record | |
| US 11,254,635 | Emodin succinyl ester compound, preparation method therefor and application thereof In force · USPTO record | In force | USPTO record | |
| US 11,564,904 | Gingko diterpene lactone composition In force · USPTO record | In force | USPTO record | |
| US 11,299,548 | Gene combination capable of high-efficiency expression of recombinant human nerve growth factor In force · USPTO record | In force | USPTO record | |
| US 11,352,331 | Crystal and Salt of 4-(NAPHTHALEN-1-YL)-4H-1,2,4-Triazole Compound and Preparation Method Therefor In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 1 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 6 no status recorded